Jardiance compared with standard heart failure medicines in Chinese patients
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at how well Jardiance (a medication for heart failure) works and how safe it is compared to other standard heart failure medicines in Chinese patients with a weak heart pump. It helps us understand which treatment works best in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with heart failure with reduced ejection fraction, and your recent heart function test (ejection fraction) is 40% or lower.
- You have had a blood test showing elevated heart strain markers (NT-proBNP >125 or BNP ≥35).
- You are starting a new treatment for heart failure, either Jardiance (empagliflozin) or one of the standard heart failure medicines like ACE inhibitors, ARBs, ARNI, beta-blockers, or MRAs.
- You have not taken any SGLT2 inhibitors (such as Jardiance) in the past 6 months.
- Your body mass index (BMI) is lower than 45.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a Chinese herbal tablet called Jia Shen can improve heart function and reduce symptoms in people with chronic heart failure caused by coronary heart disease. It aims to find a new option that may help you feel better and stay out of the hospital.
This study looks at how well the medicine Jardiance works and how safe it is for people with a certain type of heart failure where the heart's pumping function is only slightly reduced or preserved. It aims to help doctors understand the medicine's real-world effects in Chinese patients.
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This trial tests a new medicine, HJB647, in people with heart failure who have a weak heart pump. It aims to see if the drug is safe and well-tolerated. You may qualify if your heart's pumping ability is reduced and you are on a specific standard therapy.
This trial tests if dapagliflozin or acetazolamide works better for people hospitalized with heart failure who have extra fluid in their body (congestion). The study will compare how well each medication helps remove fluid when used with standard IV diuretics.
Hear when a new Heart Failure of Reduced Ejection Fraction (HFrEF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.